Clinical research progress of lorlatinib in progressive non-small cell lung cancer

Xuanlin Qi

doi:10.1117/12.2669018

24 March 2023 Clinical research progress of lorlatinib in progressive non-small cell lung cancer

Xuanlin Qi

Proceedings Volume 12611, Second International Conference on Biological Engineering and Medical Science (ICBioMed 2022); 126116H (2023) https://doi.org/10.1117/12.2669018
Event: International Conference on Biological Engineering and Medical Science (ICBioMed2022), 2022, Oxford, United Kingdom

Abstract

Lung cancer is the malignant tumors with the most incredible mortality rate and an estimated 2.2 million newly diagnosed cases worldwide, according to the World Health Organization 2020 report, significantly endangering the lives and health of people globally, which makes this kind of disease one of the most prevalent malignancies globally. 85% - 90% of all lung tumors are due to non-small cell lung cancer (NSCLC) which is a common occurrences form of lung cancer. Lorlatinib, a cutting-edge ALK inhibitor of the third-generation, has more systemic and intracranial effectiveness than ALK inhibitors of the first- and second-generations. In addition, it is effective against most single mutations known to result in ALK resistance. The treatment of patients suffering from NSCLC with Lorlatinib was approved by Japan and the US in 2018, by the EU in 2019, and by China in April 2022, when the drug should become available. For the purpose of providing a reference for clinical medication, this article reviews the clinical research progress, intracranial treatment effect and drug toxicity of Lorlatinib therapy.

Citation Download Citation

Xuanlin Qi "Clinical research progress of lorlatinib in progressive non-small cell lung cancer", Proc. SPIE 12611, Second International Conference on Biological Engineering and Medical Science (ICBioMed 2022), 126116H (24 March 2023); https://doi.org/10.1117/12.2669018

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available